alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 23

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the
Registration Statement on Form S-3 (No. 333-113841) of Millennium Chemicals Inc. of the following reports, which appear in this Annual Report on Form 10-K:



| |  |  | Our report dated March 14, 2006 on our audits of the consolidated financial statements of Millennium Chemicals Inc. relating to the financial statements, managements
assessment of the effectiveness of internal control over financial reporting and the effectiveness of internal control over financial reporting.
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Our report dated March 14, 2006 on our audits of the consolidated financial statements of Equistar Chemicals, LP relating to the financial statements, managements
assessment of the effectiveness of internal control over financial reporting and the effectiveness of internal control over financial reporting.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

/s/ PricewaterhouseCoopers LLP

PRICEWATERHOUSECOOPERS LLP

Houston, Texas

March 14, 2006
Exhibit



Exhibit 10.2





AMENDMENT NO. 2
TO THE SUPPLY AGREEMENT


THIS AMENDMENT NO. 2 (“Amendment No. 2”), TO THE Supply Agreement is entered into as of June 18, 2019 by and between Radius Health, Inc. (“Radius”) and Ypsomed AG (“Ypsomed”).


WHEREAS, Radius and Ypsomed are parties to that certain Supply Agreement having an effective date of September 30, 2015 and as amended by a first amendment as of February 7, 2017 (the “Agreement”); and


WHEREAS, pursuant to Section 4.8 of the Agreement, the Parties wish to modify the Agreement to reflect that Radius may purchase, and Ypsomed shall supply, Component Sets for use with abaloparatide finished drug product to be commercialized by Radius or its commercial partner in Canada.


NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, the Parties agree to amend the Agreement as follows: 
1.The definition of Authority in Section 1 of the Agreement is hereby amended and restated in its entirety as follows:


“ ‘Authority’ shall mean the Food and Drug Administration (“FDA”) in the United States, the Canadian Federal Department known as Health Canada, the European Medicines Agency EMEA in Europe, and/or the applicable equivalent regulatory agency or entity, governmental or non-governmental, having the responsibility, jurisdiction and authority for the grant of Authorizations in any jurisdiction in the Territory.


2.The definition of Territory in Section 1 of the Agreement is hereby amended and restated in its entirety as follows:


“ ‘Territory’ shall mean shall mean the USA, the European Union, Canada and Switzerland. Further countries may be included upon mutual agreement and in accordance with Section 4.8.”


3.For clarity, the Parties agree that Radius or its designees, including its commercialization partners, shall be responsible for the obligations and costs set forth in Section 16.1 of the Agreement.  


4.All other terms and conditions of the Agreement shall remain in full force and effect.  Capitalized terms used and not otherwise defined herein shall have the respective meanings set forth in the Agreement.


IN WITNESS WHEREOF, the parties have caused this Amendment No. 2 to be executed by their duly authorized representatives.


[signatures on following page]

















		
	RADIUS HEALTH, INC.
	YPSOMED AG


	
					
	By:
	/s/ Chhaya Shah
	 
	By:
	/s/ Frank Schiffmaun

	Name:
	Chhaya Shah
	 
	Name:
	Frank Schiffmaun

	Title:
	SVP, Technical Operations
	 
	Title:
	Senior Director, Ypsomed Delivery Systems

	Date:
	June 10, 2019
	 
	Date:
	June 18, 2019

	 
	 
	 
	By:
	/s/ Ulrike Bauer

	 
	 
	 
	Name:
	Ulrike Bauer

	 
	 
	 
	Title
	SVP, Delivery Systems








2
```

[Congressional Bills 110th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4805 Introduced in House (IH)]

110th CONGRESS
  1st Session
                                H. R. 4805

 To suspend temporarily the duty on 2-Chloro-6-Fluorobenzyl Chloride: 
        Benzene, 2,4-dichloro-1,3-dinitro-5-(trifluoromethyl)-.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           December 18, 2007

  Mr. Coble introduced the following bill; which was referred to the 
                      Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
 To suspend temporarily the duty on 2-Chloro-6-Fluorobenzyl Chloride: 
        Benzene, 2,4-dichloro-1,3-dinitro-5-(trifluoromethyl)-.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. 2-CHLORO-6-FLUOROBENZYL CHLORIDE: BENZENE, 2,4-DICHLORO-1,3-
              DINITRO-5-(TRIFLUOROMETHYL)-.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following new heading:

``      9902.01.00      2-Chloro-6-         Free         No change        No change        On or before 12/  ''.
                         Fluorobenzyl                                                       31/2011
                         Chloride:
                         Benzene, 2,4-
                         dichloro-1,3-
                         dinitro-5-
                         (trifluoromethyl)-
                          (CAS No. 55117-
                         15-2) (provided
                         for in subheading
                         2903.69.80)......

    (b) Effective Date.--The amendment made by subsection (a) applies 
to articles entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
<PAGE>

                                                            EXHIBIT NO. 23.1

              Consent of Independent Certified Public Accountants

          We have issued our report dated September 15, 2000, accompanying the
consolidated financial statements and schedule included in the Annual Report of
ProsoftTraining.com on Form 10-K for the year ended July 31, 2000.  We hereby
consent to the incorporation by reference of said report in the Registration
Statements of ProsoftTraining.com on Form S-3 (File Nos. 333-40982, 333-30336,
333-35249, 333-28993 and 333-11247) and on Form S-8 (File No. 333-19477).

                                    /s/ Grant Thornton LLP

Dallas, Texas
October 13, 2000
Charles MENSAH, Petitioner, v. UNITED STATES.

No. 18-9792

Supreme Court of the United States.

October 7, 2019

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.
```

[Congressional Bills 110th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4874 Introduced in House (IH)]

110th CONGRESS
  1st Session
                                H. R. 4874

         To suspend temporarily the duty on Solvent Violet 13.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           December 19, 2007

   Mr. Clay introduced the following bill; which was referred to the 
                      Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
         To suspend temporarily the duty on Solvent Violet 13.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SOLVENT VIOLET 13.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following new heading:

``      9902._._        Solvent Violet 13   Free         No change        No change        On or before 12/  ''.
                         (CAS No. 81-48-1)                                                  31/2011
                         (provided for in
                         subheading
                         3204.19.25)......

    (b) Effective Date.--The amendment made by subsection (a) applies 
to articles entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
Exhibit
32.2














CERTIFICATION
OF CHIEF FINANCIAL


OFFICER
REGARDING PERIODIC REPORT CONTAINING


FINANCIAL
STATEMENTS









I, Eloise
E. Schmitz, the Chief Financial Officer of CCO Holdings, LLC and CCO Holdings
Capital Corp. (the "Company") in compliance with 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby
certify that, the Company's Quarterly Report on Form 10-Q for the period
ended September 30, 2009 (the "Report") filed with the Securities and Exchange
Commission:




·
            fully
      complies with the requirements of Section 13(a) of the Securities Exchange
      Act of 1934; and




·
            the
      information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.









/s/ Eloise E.
Schmitz


Eloise E.
Schmitz


Chief
Financial Officer


(Principal
Financial Officer)


November
12, 2009
John TUBIOLO and wife, Vickie Tubiolo v. ABUNDANT LIFE CHURCH, INC.

No. 29P05.

Supreme Court of North Carolina.

March 3, 2005.

Paul I. Klein, Charlotte, for Abundant Life Church.

Joseph W. Marion, Durham, for John Tubiolo and wife.

*ORDER*

Upon consideration of the notice of appeal from the North Carolina Court of Appeals, filed by Defendant on the 11th day of January 2005 in this matter pursuant to G.S. 7A-30 (substantial constitutional question), the following order was entered and is hereby certified to the North Carolina Court of Appeals: the notice of appeal is

"Dimissed ex mero motu by order of the Court in conference, this the 3rd day of March 2005."

Upon consideration of the petition filed on the 11th day of January 2005 by Defendant in this matter for discretionary review of the decision of the North Carolina Court of Appeals pursuant to G.S. 7A-31, the following order was entered and is hereby certified to the North Carolina Court of Appeals:

"Denied by order of the Court in conference, this the 3rd day of March 2005."
<PAGE>

EXHIBIT 10.20(d)
AMENDMENT NUMBER 3 DATED JANUARY 22, 1999 TO THE MILLENNIUM
CHEMICALS INC. 1996 LONG TERM INCENTIVE PLAN

                             AMENDMENT NUMBER THREE
                                     TO THE
                        ANNUAL PERFORMANCE INCENTIVE PLAN

          WHEREAS,  Millennium  Chemicals  Inc.  (the  "Company")
maintains  the  Millennium   Chemicals  Inc.  Annual  Performance
Incentive Plan, effective as of October 1, 1996 (the "Plan");

          WHEREAS, pursuant to Section 10 of the Plan, the Board of Directors of
the Company (the "Board") reserved the right to amend the Plan; and

          WHEREAS, the Board desires to amend the Plan.

          NOW,  THEREFORE,  effective as of January 1, 1999,  the
Plan is amended as follows:

          1. The definition of "Change in Control" in Exhibit A to the Plan is
             amended by deleting Subsection (iv) of such definition in its
             entirety and substituting the following in lieu thereof:

          (iv) the stockholders of the Company approve a plan of complete
liquidation of the Company or the closing of the sale or disposition by the
Company of all or substantially all of the Company's assets other than the sale
or disposition of all or substantially all of the assets of the Company to one
or more Subsidiaries (as defined below) of the Company or to a person or persons
who beneficially own, directly or indirectly, at least fifty percent (50%) or
more of the combined voting power of the outstanding voting securities of the
Company at the time of the sale or disposition. "Subsidiary" shall have the
meaning set forth in Section 424 of the Code and the term shall also include any
partnership, limited liability company or other business entity if the Company
owns, directly or indirectly, securities or other ownership interests
representing at least fifty percent (50%) of the ordinary voting power or equity
or capital interests of such entity. Notwithstanding any of the foregoing, the
formation of Equistar Chemicals, LP ("Equistar") and the contribution of assets
by Millennium Petrochemicals Inc. to Equistar on December 1, 1997 shall not
constitute a Change in Control, and the sale or disposition of all or any part
of the Company's interests in Equistar shall not constitute a Change in Control.

          2. In all other respects, the Plan is hereby ratified and confirmed.

          IN WITNESS WHEREOF, this amendment has been executed this 22nd day of
January, 1999.

                              MILLENNIUM CHEMICALS INC.

                              By:________________________
                              George H. Hempstead, III
                              Senior Vice President



<PAGE>
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 98-7856

UNITED STATES OF AMERICA,

Plaintiff - Appellee,

versus

ROBERT W. PETTY,

Defendant - Appellant.

Appeal from the United States District Court for the District of

Maryland, at Greenbelt. Deborah K. Chasnow, District Judge. (CR97-107-DKC)

Submitted: May 11, 1999 Decided: May 21, 1999

Before HAMILTON, MICHAEL, and MOTZ, Circuit Judges.

Affirmed by unpublished per curiam opinion.

Robert W. Petty, Appellant Pro Se. Hollis Raphael Weisman, Assistant United States Attorney, Greenbelt, Maryland, for Appellee.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
* Although the district court’s judgment or order is marked as

“filed” on December 2, 1998, the district court’s records show that

it was entered on the docket sheet on December 4, 1998. Pursuant

to Rules 58 and 79(a) of the Federal Rules of Civil Procedure, it

is the date that the judgment or order was entered on the docket

sheet that we take as the effective date of the district court’s

decision. See Wilson v. Murray, 806 F.2d 1232, 1234-35 (4th Cir.

1986).

2

PER CURIAM:

Robert W. Petty appeals the district court’s order denying his

motion for a new trial. We have reviewed the record and the district court’s opinion and find no reversible error. Accordingly, we

affirm on the reasoning of the district court. See United States

v. Petty, No. CR-97-107-DKC (D. Md. Dec. 4, 1998).* We dispense

with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument

would not aid the decisional process.

AFFIRMED
I 

110TH CONGRESS 

2D SESSION H. R. 4966 

To extend the temporary suspension of duty on Isobutyl 4-hydroxybenzoate 

and its sodium salt. 

IN THE HOUSE OF REPRESENTATIVES 

JANUARY 15, 2008 

Mrs. MYRICK introduced the following bill; which was referred to the 

Committee on Ways and Means 

A BILL 

To extend the temporary suspension of duty on Isobutyl 

4-hydroxybenzoate and its sodium salt. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. ISOBUTYL 4-HYDROXYBENZOATE AND ITS SO4 DIUM SALT. 

5 (a) IN GENERAL.—Heading 9902.22.41 of the Har6 monized Tariff Schedule of the United States (relating to 

7 Isobutyl 4-hydroxybenzoate and its sodium salt) is amend8 ed by striking ‘‘12/31/2009’’ and inserting ‘‘12/31/2011’’. 

9 (b) EFFECTIVE DATE.—The amendment made by 

10 subsection (a) applies to goods entered, or withdrawn from 


ccoleman on PRODPC75 with BILLS
2 

•HR 4966 IH

1 warehouse for consumption, on or after the 15th day after 

2 the date of the enactment of this Act. 

Æ 


ccoleman on PRODPC75 with BILLS
CHARGEPOINT, INC., Petitioner v. SEMACONNECT, INC.

No. 19-521

Supreme Court of the United States.

January 27, 2020

Motion of Jeremy C. Doerre for leave to file a brief as *amicus curiae* granted. Petition for writ of certiorari to the United States Court of Appeals for the Federal Circuit denied.
[Federal Register Volume 87, Number 117 (Friday, June 17, 2022)]
[Notices]
[Page 36485]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-13117]


-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission


Combined Notice of Filings

    Take notice that the Commission has received the following Natural 
Gas Pipeline Rate and Refund Report filings:

Filings in Existing Proceedings

    Docket Numbers: RP21-778-006.
    Applicants: Southern Star Central Gas Pipeline, Inc.
    Description: Compliance filing: Rate Case (RP21-778) Settlement 
Filing to be effective 11/1/2021.
    Filed Date: 6/10/22.
    Accession Number: 20220610-5156.
    Comment Date: 5 p.m. ET 6/22/22.

    Any person desiring to protest in any the above proceedings must 
file in accordance with Rule 211 of the Commission's Regulations (18 
CFR 385.211) on or before 5:00 p.m. Eastern time on the specified 
comment date.

Filings Instituting Proceedings

    Docket Numbers: RP22-977-000.
    Applicants: Gulf South Pipeline Company, LLC.
    Description: Sec.  4(d) Rate Filing: Filing to Incorporate Approved 
Changes from RP22-738-000 to be effective 6/1/2022.
    Filed Date: 6/10/22.
    Accession Number: 20220610-5088.
    Comment Date: 5 p.m. ET 6/22/22.

    Docket Numbers: RP22-978-000.
    Applicants: El Paso Natural Gas Company, L.L.C.
    Description: Sec.  4(d) Rate Filing: Negotiated Rate Agreement 
Update (Pioneer July-Sept 2022) to be effective 7/1/2022.
    Filed Date: 6/10/22.
    Accession Number: 20220610-5173.
    Comment Date: 5 p.m. ET 6/22/22.

    Any person desiring to intervene or protest in any of the above 
proceedings must file in accordance with Rules 211 and 214 of the 
Commission's Regulations (18 CFR 385.211 and 385.214) on or before 5:00 
p.m. Eastern time on the specified comment date. Protests may be 
considered, but intervention is necessary to become a party to the 
proceeding.
    The filings are accessible in the Commission's eLibrary system 
(https://elibrary.ferc.gov/idmws/search/fercgensearch.asp) by querying 
the docket number.
    eFiling is encouraged. More detailed information relating to filing 
requirements, interventions, protests, service, and qualifying 
facilities filings can be found at: http://www.ferc.gov/docs-filing/efiling/filing-req.pdf. For other information, call (866) 208-3676 
(toll free). For TTY, call (202) 502-8659.

    Dated: June 13, 2022.
Debbie-Anne A. Reese,
Deputy Secretary.
[FR Doc. 2022-13117 Filed 6-16-22; 8:45 am]
BILLING CODE 6717-01-P
Exhibit 23.1

Independent
Auditors ConsentThe
Board of DirectorsInformation Architects Corporation

We
consent to the incorporation on Form 10KSB with respect to our report dated March 3, 2005
of the balance sheet of Information Architects Corporation as of December 31, 2003 and the related statements of operations, shareholders equity and cash flows
for the year then ended.

| |  | Jaspers + Hall, PCBY: /S/ Jaspers + Hall, PC
Jaspers + Hall, PCDenver Colorado
April 13, 2005
| |  | -----------------------------------------------------------------------------------------------------------
Employment Agreement


 Exhibit 10.123 
 [LETTERHEAD OF EOS INTERNATIONAL, INC.] 
  
 February 3, 2004 
  
 Peter A. Lund 
 32 East 64th Street 
 New York, NY 10021 
  
 Dear Mr. Lund: 
  
 This letter
amends the letter dated July 24, 2000, as amended October 21, 2002, from Eos International, Inc. (the “Company”) to you regarding your employment by the Company (the “Letter”). By signing below you agree as follows: 

 

	 	1.	Pursuant to Paragraph A of the Letter, you were entitled to an annual salary of $300,000. Per the amendment letter dated October 21, 2002, you and the Company had agreed effective
July 1, 2002 until otherwise agreed by you and the Company that your salary would be $3,000 per month. You and the Company have agreed effective January 16, 2004 until otherwise agreed by you and the Company that you will not receive a salary.


  

	 	2.	Except to the extent amended hereby and by the letter dated October 21, 2002, the Letter shall continue in full force and effect. 

  
 If the foregoing correctly sets forth our agreement with respect to the
matters set forth herein, please so indicate by signing two copies of this Agreement and returning one signed copy to the Chief Financial Officer of the Company, whereupon this Agreement shall constitute our binding agreement with respect to the
matters set forth herein. 
  

			
	 Very truly yours,

	
	 EOS INTERNATIONAL, INC.

		
	 By:
	 	    JOSE FERREIRA, JR.        
	 	 	

	 Name:
	 	Jose Ferreira, Jr.
	 Title:
	 	President and CEO


  

			
	AGREED AND ACCEPTED BY:
		
	 	 	    PETER A. LUND        
	 	 	

	 Name:
	 	Peter A. Lund
	 Date:
	 	 February 3, 2004
EXHIBIT
      32.1





CERTIFICATION
                REQUIRED BY 18 U.S.C. SECTION 1350(AS
                ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF
                2002)





I,
      Charles R. Eitel, as Chief Executive Officer of Simmons Company (the “Company”),
      certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section
      906
      of the Sarbanes-Oxley Act of 2002), that to my knowledge:





(1)
      the Quarterly Report on Form 10-Q of the Company for the quarter ended September
      30, 2006 (the “Report”), being filed with the U.S. Securities and Exchange
      Commission on the date hereof, fully complies with the requirements of Section
      13(a) or 15(d) of the Securities Exchange Act of 1934, as amended;
      and





(2)
      the information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.





Date:
      November 13, 2006     /s/
      Charles R. Eitel


Name:
      Charles R. Eitel


Title:
      Chief Executive Officer








A
      signed original of this written statement required by Section 906 has been
      provided to Simmons Company and will be retained by Simmons Company and
      furnished to the Securities and Exchange Commission or its staff upon
      request.
<PAGE> 1
                        EXHIBIT 12(b)
                              
             CHASE PREFERRED CAPITAL CORPORATION
      Computation of ratio of earnings to fixed charges
          and preferred stock dividend requirements
<TABLE>
<CAPTION>

                                    For the Period from
                            Inception (September 18, 1996)
                            through December 31, 1996
                             (in thousands, except ratio):
<S>                                     <C>
Net income                              $22,085

Fixed charges:
  Advisory fees                              71

Total fixed charges                          71

Earnings before fixed charges           $22,156

Fixed charges, as above                 $    71

Preferred stock dividend requirements    12,746

Fixed charges including preferred       $12,817
     stock dividends

Ratio of earnings to fixed charges and
     preferred stock
     dividend requirements                 1.73



</TABLE>